Investment Analysts’ Recent Ratings Changes for Regeneron Pharmaceuticals (REGN)

A number of research firms have changed their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

  • 12/14/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $430.00 price target on the stock.
  • 12/12/2017 – Regeneron Pharmaceuticals is now covered by analysts at Deutsche Bank AG. They set a “hold” rating and a $397.00 price target on the stock.
  • 12/1/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $380.00 price target on the stock, down previously from $480.00.
  • 11/30/2017 – Regeneron Pharmaceuticals was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating.
  • 11/28/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 11/28/2017 – Regeneron Pharmaceuticals had its price target lowered by analysts at BTIG Research from $520.00 to $480.00. They now have a “buy” rating on the stock.
  • 11/27/2017 – Regeneron Pharmaceuticals was given a new $444.00 price target on by analysts at BMO Capital Markets. They now have a “hold” rating on the stock.
  • 11/22/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $520.00 price target on the stock.
  • 11/16/2017 – Regeneron Pharmaceuticals had its price target lowered by analysts at Evercore ISI from $605.00 to $445.00. They now have an “outperform” rating on the stock.
  • 11/14/2017 – Regeneron Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Regeneron’s third-quarter results were impressive as both earnings and sales beat estimates driven by strong Eylea’s sales. Eylea continues to perform well. Dupixent launch in the United States for moderate-to-severe atopic dermatitis is progressing well. The drug was also approved in Europe. The geographic expansion of the drug will further boost sales. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. The approval of new drugs like Kevzara and Dupixent provide a significant boost to the top-line and reduce the company’s dependence on Eylea for growth. Prospects of PCSK9 inhibitors, a new class of cholesterol-lowering treatments with blockbuster potential, gained instant popularity even before hitting the market. Shares have outperformed the industry so far in 2017. However, sales of Praluent have failed to impress payer utilization management restrictions in the United States.”
  • 11/13/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $540.00 price target on the stock.
  • 11/9/2017 – Regeneron Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $490.00 to $463.00. They now have an “equal weight” rating on the stock.
  • 11/9/2017 – Regeneron Pharmaceuticals had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $425.00 price target on the stock, down previously from $473.00.
  • 11/9/2017 – Regeneron Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $491.00 to $479.00. They now have a “market perform” rating on the stock.
  • 11/9/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $480.00 price target on the stock.
  • 11/3/2017 – Regeneron Pharmaceuticals was upgraded by analysts at Robert W. Baird from an “underperform” rating to a “neutral” rating.
  • 10/31/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 10/23/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $540.00 price target on the stock.
  • 10/20/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Barclays PLC from an “equal weight” rating to an “underweight” rating. They now have a $395.00 price target on the stock, down previously from $450.00.
  • 10/16/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 10/16/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They wrote, “Cara announced this morning that the company has completed an End of Phase 2 mtg with FDA around CR845 in Pruritus associated with Chronic Kidney Disease. We spoke w/ mgmt for an update. Cara plans to initiate one Phase 3 trial of IV CR845 in the U.S. in 4Q17, followed by a second Phase 3 trial in Europe in early 2018. Details on size and design are expected during 3Q17 conference call in a few wks. Although mgmt not providing guidance on timing to top-line results, we believe NDA submission YE19 and launch YE20 still appears feasible.””

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at $383.12 on Friday. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $340.09 and a fifty-two week high of $543.55. The stock has a market cap of $41,011.62, a P/E ratio of 33.05, a PEG ratio of 1.50 and a beta of 1.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same period last year, the company earned $3.13 earnings per share. The firm’s revenue was up 23.0% compared to the same quarter last year. sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

In related news, Director Michael S. Brown sold 1,500 shares of the business’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Charles A. Baker sold 2,000 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.